Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Yevsa, TetyanaEbensen, Thomas
Fuchs, Barbara
Zygmunt, Beata
Libanova, Rimma
Gross, Roy
Schulze, Kai

Guzmán, Carlos A
Issue Date
2013-01
Metadata
Show full item recordAbstract
Bordetella bronchiseptica is an important pathogen causing a number of veterinary respiratory syndromes in agriculturally important and food-producing confinement-reared animals, resulting in great economic losses annually amounting to billions of euros worldwide. Currently available live vaccines are incompletely satisfactory in terms of efficacy and safety. An efficient vaccine for livestock animals would allow reducing the application of antibiotics, thereby preventing the massive release of pharmaceuticals into the environment. Here, we describe two new potential vaccine strains based on the BB7865 strain. Two independent attenuating mutations were incorporated by homologous recombination in order to make negligible the risk of recombination and subsequent reversion to the virulent phenotype. The mutations are critical for bacterial metabolism, resistance to oxidative stress, intracellular survival and in vivo persistence. The resulting double mutants BB7865 risA aroA and BB7865 risA dapE were characterized as promising vaccine candidates, which are able to confer protection against colonization of the lower respiratory tract after sublethal challenge with the wild-type strain.Citation
Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology. 2013, 15 (1):64-76 Environ. Microbiol.Affiliation
Department of Vaccinology and Applied Microbiology, Helmholtz Centre for Infection Research, D-38124 Braunschweig, Germany.Journal
Environmental microbiologyPubMed ID
22676396Type
ArticleLanguage
enISSN
1462-2920ae974a485f413a2113503eed53cd6c53
10.1111/j.1462-2920.2012.02779.x
Scopus Count
The following license files are associated with this item:
Related articles
- Use of a genetically defined double mutant strain of Bordetella bronchiseptica lacking adenylate cyclase and type III secretion as a live vaccine.
- Authors: Mann P, Goebel E, Barbarich J, Pilione M, Kennett M, Harvill E
- Issue date: 2007 Jul
- Membrane Vesicles Derived from Bordetella bronchiseptica: Active Constituent of a New Vaccine against Infections Caused by This Pathogen.
- Authors: Bottero D, Zurita ME, Gaillard ME, Bartel E, Vercellini C, Hozbor D
- Issue date: 2018 Feb 15
- An aromatic amino acid auxotrophic mutant of Bordetella bronchiseptica is attenuated and immunogenic in a mouse model of infection.
- Authors: McArthur JD, West NP, Cole JN, Jungnitz H, Guzmán CA, Chin J, Lehrbach PR, Djordjevic SP, Walker MJ
- Issue date: 2003 Apr 11
- Use of Bordetella bronchiseptica and Bordetella pertussis as live vaccines and vectors for heterologous antigens.
- Authors: Stevenson A, Roberts M
- Issue date: 2003 Jul 15
- Use of a rationally attenuated Bordetella bronchiseptica as a live mucosal vaccine and vector for heterologous antigens.
- Authors: Stevenson A, Roberts M
- Issue date: 2002 May 22